DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES
- Tumors have latent vulnerabilities that can be identified through ETA.
- Agnostic to stage, grade, anatomy or morphology.
- Integrational multi-analyte interrogation of tumor interactome and tumor function.
- Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.
DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES
- Tumors have latent vulnerabilities that can be identified through ETA.
- Agnostic to stage, grade, anatomy or morphology.
- Integrational multi-analyte interrogation of tumor interactome and tumor function.
- Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.
442 Genes
417 Genes
51 Genes
Features
✓Targeted Therapy : Evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors.
✓Immunotherapy : Helps inform immunotherapy decisions by including genomic signatures such as microsatellite instability (MSI), tumor mutational burden (TMB) and PDL1 status.
✓Simplified Report : All results are provided in a simplified report, with indications for approved therapies and genomic highlights.
✓452 Genes (SNVs, CNAs, Fusions and Indels).
✓Turnaround time is less than 3 working days from the day we receive the tissue sample.
Comparison
| Platform | Parameters | FoundationOne CDx* | Celldx |
| NGS | Number of Genes | 324 | 452 |
| SNVs + Indels | 309 | 442 | |
| SNAs | 309 | 417 | |
| Fusions | 36 | 51 | |
| TMB | ✓ | ✓ | |
| MMR | ✗ | ✓ | |
| HRD | ✗ | ✓ | |
| IHC | PD-L1 | ✓ (optional) |
✓ |
| STR | IHC | MSI | ✓ | ✓ |
| Patient Benefits | TAT | 2 Weeks | 48 Hours |
| Cost |  |
 |
|
* FoundationOne®CDx are registered trademarks of Foundation Medicine, Inc.
SNVs + INDELs
SNVs + INDELs + CNAs
GENE FUSIONS
DOWNLOAD BROCHURE + SAMPLE REPORT
CONTACT US